



17991 Englewood Drive, Suite A, Middleburg Heights, OH 44130 +1.800.459.8500 P; +1.440.243.1334 F

PR Contact: Cristy Berg, VP Communications
cberg@daylightmedical.com

MoonBeam™3 is the first and only UV-C 254 nanometer system proven to destroy SARS-CoV-2 (Coronavirus).

And in under 4 seconds!

Diversey MoonBeam™3, distributed by Daylight Medical, used to test effectiveness at Fujita Health University Japan

October 2020 – A recent study conducted by Murata Takayuki, Ph.D, Virology and Parasitology, Fujita Health University, Japan, performed antimicrobial effectiveness testing using Diversey MoonBeam™3 on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), obtained from Kanagawa Prefectural Institute of Public Health, Japan (SARS-CoV-2/Hu/DP/Kng/19-020). Diversey MoonBeam3 uses germicidal UV-C light (254 nm wavelength) to disinfect high-touch surfaces and is used in the world’s leading hospitals to reduce the spread of HAI (healthcare-associated infections) such as MRSA, VRE, MDR-Gram negative, norovirus and *C. diff* spores. The study was conducted in cooperation with Daylight Medical (USA), Diversey Incorporated (USA), and Fujidenolo Co., LTD (Japan).

In the University’s cooperation with industry, Dr. Takayuki tested the live COVID-19 strain on samples received August 19, 2020. The study began August 24, 2020, and was completed on September 15, 2020, at the BSL3 Lab, Fujita Health University. Due to the nature of the test samples, the test was performed within a BSC biologic hazard/safety cabinet. Dose rate and accumulated UV-C energy delivered was verified with a LUTRON-254SD dosimeter and NiGK Corporation Super High Sensitivity UV-C Irradiation Color Sensors at Daylight Medical Headquarters in Middleburg Heights, Ohio.

The optimized bulb and reflector geometry of MoonBeam3 was demonstrated to provide exceptional performance. At two-seconds of MoonBeam3 exposure, a 99.99% (4.21 log 10) reduction of organisms was confirmed (TCID50/mL). At four-seconds, the MoonBeam3 left no detectable organisms, a >99.9999% (>6 log 10) reduction.

“MoonBeam3 is the first germicidal UV-C 254 nanometer system to demonstrate efficacy against COVID-19. Given typical distance and incident angles and exposure times of 90- to 180-second range, the UV-C energy delivered by MoonBeam3 demonstrates efficacy against COVID-19 for wide-area use,” stated Gary W, Enos, President, Daylight Medical. “The system’s mobility and ease of positioning in tight spaces, such as school buses, medical transport and RTA, combined with fast delivery of effective UV-C doses makes it the ideal solution whenever and wherever it’s needed. In addition to small spaces, its versatility enables disinfection of a wide variety of pathogens over distances greater than six-feet (183 cm) deep and 10-feet (304cm) wide, such as a hospital room. MoonBeam3 is the perfect solution for proven and safe disinfection during this pandemic and beyond,” Enos added.

Fujita Health University is no stranger to the virus. At the height of the pandemic, Fujita Health University was one of the first hospitals to accept suspect COVID-19 cases. Fujita Health University Okazaki Medical Center cared for 128 asymptomatic carriers who were admitted after vacationing on the Diamond Princess Cruise ship, which was quarantined at the port of Yokohama. American passengers returning to the USA for care and quarantine were transported via bus and ambulance. MoonBeam3 was used to disinfect the vehicles after the passengers disembarked.

MoonBeam3 is third-party efficacy tested. Uniquely designed for maximum versatility, its three articulating arms can be positioned vertically, horizontally or angled, allowing the dose to get close or distanced to surfaces. Incredibly easy to use and operate, a user simply plugs it in, positions the arms and presses start. The system will automatically run one of four selectable cycle times — from 90 seconds to 10 minutes — and indicate when the cycle is complete. Built-in safety features will interrupt the cycle if motion or acceleration is detected, helping to guard against accidental human exposure to the UV-C light.

About Daylight Medical

Our mission is simple: to provide our valued customers with innovative products that allow you to offer the highest level of care to your patients, your customers and your staff. Daylight Medical is a distributor for Diversey MoonBeam™3 with exclusive distribution in North America, Canada and Japan. Daylight Medical has appointed Codonics, Inc. as distributor of Diversey MoonBeam™3 for its international sales. Diversey MoonBeam™3 is manufactured by Codonics in Middleburg Heights, Ohio. For more information, visit us at www.daylightmedical.com.

About Diversey

Diversey's purpose is to protect and care for people every day. Diversey has been, and always will be, a pioneer and facilitator for life. We constantly deliver revolutionary cleaning and hygiene technologies that provide total confidence to our customers across all of our global sectors, including cleaning products, systems and services that efficiently integrate chemicals, machines and sustainability programs. This makes us unique among leading global hygiene and cleaning companies. Everything we do has our customers' needs at its heart and is based on the belief that cleaning and hygiene are life essentials. With over 95 years of expertise, we safeguard our customers' businesses, contributing to productivity improvements, lower total operating costs and brand protection. For more information, visit us at www.diversey.com.

About Fujidenolo

Fujidenolo is an engineering and precision manufacturing company, and a Daylight Medical authorized distributor of Diversey Moonbeam3 in Japan. For more information, visit us at www.fujidenolo.co.jp.

About Fujita Health University

The Fujita Health University Hospital, a teaching university hospital, is one of the largest in Japan in terms of the number of beds, and students are offered exceptional opportunities for the most advanced and comprehensive experience before they embark upon their career. In addition, we also strongly focus on cutting-edge research. For example, we start operations at the Regenerative Medicine Support Promotion Facility in 2018 to take a lead in the field of regenerative medicine. The University is committed to providing many opportunities to enable students to learn from clinical experts who are dedicated to pursuing the most advanced research in the world while students develop a proactive attitude toward self-learning through tailored instructions. For more information, visit us at www.fujita-ju.ac.jp

###